Importantly, adjunct therapy with fibrates, e.g., fenofibrate and bezafibrate (pan-PPAR agonist; not FDA-approved), improves biochemical markers of cholestasis, including reducing elevated serum alkaline phosphatase (ALP) and reducing the toxicity of the bile acid pool in PBC and PSC [14,15,16,17,18,19]. Here, PPARA is linked to cholestasis.